This January Is Pharma M&A Month
Halfway through the month of January 2016, 12 pharmaceutical deals have been announced, with a total of $32.8 billion. You might think that’s a result of the annual JP Morgan Healthcare Summit that’s held every year in the second week of January. That’s only half right. Last year, only nine pharma deals were announced the entire month of January, with six of them in the first two weeks. In 2014, there were 14 pharma deals in January, 11 of which were announced in the first two weeks. The biggest deal in the sector this month, Shire plc’s (NASDAQ: SHPG) $32 billion acquisition of Baxalta Inc. (NYSE: BXLT), was in the works long before the Summit, however. Shire... Read More »Pharma’s Big Year in M&A
With one week to go in 2015, there are still a few big pharmaceutical deals in the works. Shire plc (NASDAQ: SHPG) is now in friendly talks to take over Baxalta International Inc. (NYSE: BXLT) for a price rumored to be above $30 billion. By who’s waiting for 2016? Here is a preliminary tally of the year in pharmaceutical M&A, and how it compares to previous years. Spoiler alert: 2015 is another record year in dollar value. Pharmaceutical M&A, 2011 to 2015* 20112012201320142015 Deal volume115103150188167 % change11%-10%46%25%-11% Deal value$44.1 billion$38.1 billion$66.7 billion$213.3 billion$297.4 billion % change11%-14%76%219%40% *= thru Dec.... Read More »Martin Shkreli, We Hardly Knew Ye
Actually, we know Martin Shkreli, CEO of KaloBios Pharmaceuticals (NASDAQ: KBIO), all too well. The brash young man was arrested by the Federal Bureau of Investigations yesterday in Manhattan, on charges of fraud relating to his days at a hedge. Just weeks before, as then-CEO of privately held Turing Pharmaceuticals, he became the poster child of drug price gougers, having boosted the price of a long-marketed generic drug by 5000%, from $13.50 per pill to $750. The revelations in a New York Times story brought swift recriminations from all sides, including presidential candidates. The most striking note for us, as health care database wonks, is that Shkreli launched his first biotech... Read More »Pfizer’s Acquisition Trail
Pfizer Inc. (NYSE: PFE) is a well-oiled acquisition machine, with at least 107 announced acquisitions since 1998. Including yesterday’s announcement of its $160 billion deal for Irish drug maker Allergan plc (NYSE: AGN), the largest-ever health care transaction, Pfizer has spent more than $461 billion on those 107 deals. Thirteen of those disclosed prices of $1 billion or more. Here are the five biggest deals announced. Company AcquiredDatePrice Allergan plcNovember 23, 2014$160 billion Warner-Lambert CompanyNovember 4, 1999$114 billion Wyeth, Inc. January 26, 2009$68 billion Pharmacia CorporationJuly 15, 2002$56 billion Hospira, Inc. February 5, 2015$17... Read More »Health Care M&A Passes Half-a-Trillion $ Mark
Thanks to today’s announcement that Pfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) agreed to a $160 billion merger, 2015’s total for health care mergers and acquisitions now stands at $549.4 billion. That’s 42% higher than last year’s full total of $387 billion, an amount we thought would stand for at least a few years. Deal volume for the year is now about 1,285, just 2% below last year’s record of 1,312 transactions. And there’s still a month left to go in 2015. Stay tuned. Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
